ABUS (Arbutus Biopharma Corp) Net Profit

Official company branding of Arbutus Biopharma Corp (ABUS)

The share price history of Arbutus Biopharma (ABUS) reflects the dynamics of a company whose success relies on hepatitis B therapy test results and revenue from LNP patents, which constitutes 0.15. The business is scaling through the development of high-margin global RNA drugs. Currently, antiviral production capacities are being upgraded to ensure the future mass production of medicines in cleanrooms.

ABUS (Tekmira Pharmaceuticals) Company Net Income history from 07/04/2022 to 10/31/2026

Comprehensive metric breakdowns and analytics for Arbutus Biopharma Corporation (ABUS)

- price and consensus price forecast:
Stock Quotes Tekmira Pharmaceuticals|ABUS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Tekmira Pharmaceuticals|ABUS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Arbutus Biopharma|ABUS - Company Book Value|Market Value to Book Value Ratio arbutusbio.com|ABUS - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Arbutus Biopharma|ABUS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Arbutus Biopharma Corp|ABUS - Company Aggregate Debts|Debts to Book Value Tekmira Pharmaceuticals|ABUS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Arbutus Biopharma|Quick Ratio arbutusbio.com
- net income and valuation multiples indicators:
ABUS - Company Net Income
Fundamental valuation:ABUS Tekmira Pharmaceuticals
Mass-produced product of Arbutus Biopharma Corp

The indicator is calculated as the difference between total revenues and all operating expenses, reflecting the final financial result. This trend captures current operating efficiency and capital stability without waiting for quarterly reports. For Arbutus Biopharma (ABUS), this metric is critical, as the outsourcing of production and clinical trials directly impacts the cost structure. Analyzing the company's net reported profit helps identify risks of overspending on external contractors. The stability of this curve confirms the viability of the business model.

Main competitors

Net Income Arrowhead Corp|MIRM (Mirum Pharmaceuticals) - Net Profit|Net Profit Dynavax Corp|Net Income IVA (Inventiva)|GYRE (Gyre Therapeutics Inc) - Final Profit|Company Net Income Assembly Biosciences Inc ASMB|Galectin Therapeutics, Inc. - Company Net Income|Genfit Corp - Net Profit|Net Financial Result DURECT Corporation DRRX|ALGS (aligos.com) - Net Income|BIVI (BioVie) - Company Net Income|GLMD (Galmed Pharmaceuticals Ltd) - Net Profit|Company Net Income ENDRA Corp NDRA|Company Net Income Hepion Pharmaceuticals (HEPA)